Life Sciences Ontario
Life Sciences Ontario (LSO) strives to be the unified Voice of Life Sciences in Ontario by representing the interests of the diverse life sciences community in the province through advocacy, education, facilitation of economic development and promotion of the industry locally, nationally and internationally. Together we are a strong, innovative sector with significant socioeconomic contributions to the province of Ontario. We hope you will consider joining LSO and help us to achieve our vision for Ontario's life sciences sector - "Diversity of Members, Unity of Voice".
Life Sciences Ontario Announces 2014 Award Winners
Tuesday, December 10, 2013
Life Sciences Ontario (LSO) announced today the 2014 LSO award winners. Each year, LSO recognizes outstanding achievements in the life sciences sector. The awards will be presented at the LSO Annual Awards Gala on February 26, 2014 at the historic Liberty Grand.
Life Sciences Ontario Fall Symposium to Feature Public-Private Sector Policy Debate
Tuesday, November 26, 2013
Public sector needs versus private sector policy will be the main topic of discussion in a debate featuring leaders (past and present) from the government and industry at the 4th Annual Life Sciences Ontario Symposium “Catalyzing Collisions and Clusters”. This full day symposium will be held at the Living Art Centre in Mississauga, December 11, 2013. The theme of the symposium is designed to highlight the importance of creating dialogue amongst key stakeholders in order to build a stronger life sciences cluster in Ontario.
Supporting Research and Innovation in Health Technology Sector
Thuesday, November 21, 2013
Ontario Creates New Council to Study Sector Innovation- Ministry of Research and Innovation
Ontario is helping create jobs in the province's growing health technology sector through the Ontario Health Innovation Council to bring new health care products to market, in partnership with Ontario's health care system
Paladin Labs Inc. to be Acquired by Endo Health Solutions Inc.
Tuesday, November 12, 2013
Paladin Labs Inc. today announced that it has reached a definitive agreement to be acquired by Endo Health Solutions, a leading U.S.-based specialty pharmaceutical company, in a stock and cash transaction valued at approximately $1.7 billion. Pursuant to the acquisition, both Endo and Paladin will be acquired by a newly-formed Irish holding company ("New Endo"). At $77 per Paladin share, the transaction represents a 20% premium to the Paladin closing share price on November 4, 2013 of $63.91 and a 25% premium to Paladin's 3 month volume weighted average share price of $61.67.